# Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: ZURA
Company: Zura Bio
Source: Zura Bio
Published: 2026-05-04 20:05 EST
Original Source URL: https://investors.zurabio.com
## Summary

HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

## Article Body
HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory
## Recent Company News
- 2026-05-13 11:30 EST — [Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer](https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer) — Source: Zura Bio
- 2026-05-07 11:30 EST — [Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-05-04 20:05 EST — [Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Zura Bio
- 2026-03-19 20:05 EST — [Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-03-05 11:30 EST — [Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress](https://biopharmsignal.com/news/ZURA/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress) — Source: Zura Bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)